Journal of Nanomedicine & Nanotechnology

Preformulation study of olopatadine hydrochloride for the treatment ocular allergy

4^th International Conference on Nanotek & Expo

December 01-03, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Umay Merve Guven, Murat Sami Berkman and YaseminYazan

Posters: J Nanomed Nanotechnol

Abstract:

Ocular allergy or allergic diseases of the eye are one of the most frequently encountered disorders of the ocular surface. Among the ocular allergies allergic conjunctivitis is the most common type of allergy. It occurs seasonal or permanently, followed with the complaints of slight redness and swelling of the eyelids, itching, tearing, burning. Especially the treatment of allergic conjunctivitis is regular use of the drugs however what is important this type of therapy is the adjustment of dose. Conventional anti-allergic eye drops and various delivery systems can result in poor drug bioavailability due to the unique ocular anatomy and physiology. The novel approach in ocular treatment using controlled drug delivery system is to maintain prolonged residence time of the active material at the side of action. Olopatadine hydrochloride is an antiallergic agent with histamine H1 receptor antagonistic action used in ocular allergy and is classified as a second generation antihistamines. This generation causes fewer side effects than the other members. Therefore Olopatadine Hydrochloride was selected as an active material. In this study chitosan based nanaoparticle formulation studies were performed aiming enhanced corneal contact time with the help of mucoadeshive character of the natural polymer; Chitosan.

Biography :

Umay Merve Guven got Bachelor?s degree in 2010/June from Anadolu University, Faculty of Pharmacy. She started her PhD programme in 2011/February. Since 2012 she has been working as a Research Assistant at the Department of Pharmaceutical Technology at Anadolu University.